...
首页> 外文期刊>BMC Nephrology >Timing of kidney biopsy in type 2 diabetic patients: a stepwise approach
【24h】

Timing of kidney biopsy in type 2 diabetic patients: a stepwise approach

机译:2型糖尿病患者肾活检时序:逐步的方法

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Diabetic nephropathy (DN) is the most prevalent cause of renal disease in type 2 diabetic patients and is usually diagnosed clinically. A kidney biopsy is considered when non-diabetic renal disease (NDRD) is suspected, such as rapid progression in renal function impairment and severe proteinuria. Still, there is yet no consensus on the timing of kidney biopsy in type 2 diabetic patients. This study aims to identify markers that can help differentiate between DN and NDRD and guide the decision of kidney biopsy. We retrospectively reviewed patients with type 2 diabetes who received kidney biopsy from 2008 to 2017 at Taipei Veterans General Hospital. Ophthalmologist consultation and outpatient records, diagnosis of kidney biopsy, laboratory data, and clinical characteristics were collected. This study enrolled 160 type 2 diabetic patients, among which 120 (75%) had isolated DN and 40 (25%) had NDRD ± DN (26 had isolated NDRD, and 14 had NDRD superimposed on DN). In multivariate logistic regression analysis, DM duration (odds ratio [OR]: 0.907; 95% confidence interval [CI]: 0.842–0.977; P?=?0.01), diabetic retinopathy (OR: 0.196; 95% CI: 0.061–0.627; P?=?0.006), and urinary RBC (OR: 1.068; 95% CI: 1.024–1.115; P?=?0.002) were independent predictors of NDRD. In patients with diabetic retinopathy (n?=?112, 70%), the presence of proliferative diabetic retinopathy, pan-retinal photocoagulation, and hematuria were factors predicting NDRD; and in patients without diabetic retinopathy (n?=?48, 30%), short DM duration and hematuria were factors predicting NDRD. Using diabetic retinopathy, DM duration, and hematuria, we developed a 3-step approach to stratify patients into three categories with the different likelihoods of having NDRD. Then different strategies could be taken accordingly. Our stepwise approach is easy to follow and may serve as an appropriate and useful tool to help clinicians in making decisions of kidney biopsy in type 2 DM patients presenting with kidney diseases.
机译:糖尿病肾病(DN)是2型糖尿病患者肾病最普遍的原因,通常在临床上诊断。当怀疑非糖尿病肾病(NDRD)时,考虑肾脏活检,例如肾功能障碍和严重蛋白尿的快速进展。尽管如此,患有2型糖尿病患者的肾活检时期尚未共识。本研究旨在识别可以帮助区分DN和NDRD的标记,并指导肾脏活检的决定。我们回顾性地审查了2型糖尿病患者,他们在台北退伍军人综合医院从2008年到2017年接受了肾脏活检。收集眼科医生咨询和门诊记录,诊断肾活检,实验室数据和临床特征。本研究注册了160型2型糖尿病患者,其中120(75%)分离DN,40(25%)具有NDRD±DN(26次分离的NDRD,14个具有叠加在DN上的NDRD)。在多变量逻辑回归分析中,DM持续时间(差距[或]:0.907; 95%置信区间[CI]:0.842-0.977; p?= 0.01),糖尿病视网膜病变(或:0.196; 95%CI:0.061-0.627 ; p?= 0.006)和尿RBC(或:1.068; 95%CI:1.024-1.115; p?= 0.002)是NDRD的独立预测因子。在患有糖尿病视网膜病变的患者中(n?= 112,70%),增殖性糖尿病视网膜病变,泛视网膜光凝和血尿的存在是预测NDRD的因素;在没有糖尿病视网膜病变的患者中(N?= 48,30%),短DM持续时间和血尿是预测NDRD的因素。使用糖尿病视网膜病变,DM持续时间和血尿,我们开发了一个三步的方法,将患者分成三类,具有NDRD的不同可能性。然后可以相应地采取不同的策略。我们的逐步方法易于遵循,可以作为适当和有用的工具,以帮助临床医生在患有肾脏疾病的2型DM患者中制定肾脏活检的决定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号